Haruhiko Ninomiya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Haruhiko Ninomiya has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Toshiro Nagasawa
Division of Hematology, Institute of Clinical Medicine, University of Tsukuba , Japan
4 shared publicationsYasuko Kawashima
From the Division of Hematology, the Institute of Clinical Medicine, and the College of Medical Technology, University of Tsukuba, Tsukuba, Ibaraki, Japan
3 shared publicationsJ. Takasaki
Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., Tsukuba, Japan JP
1 shared publication- Jun Takasaki
Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., 21 Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan
1 shared publication T. Nagasawa
Division of Hematology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Japan JP
1 shared publicationT. Urasaki
Division of Hematology, Institute of Clinical Medicine, University of Tsukuba, Japan
1 shared publication
Latest Publications
- 1 January 2001
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 69 (1) , 105-112
Pivotal role of 5-lipoxygenase in the activation of human eosinophils: platelet-activating factor and interleukin-5 induce CD69 on eosinophils through the 5-lipoxygenase pathway
CD69 is an activation-related cell surface molecule on human eosinophils. It has been reported that interleukin (IL)-5, but not platelet-activating factor (PAF), can induce CD69 on human eosinophils in vitro. In this study, PAF induced CD69 intensely on eosinophils from patients with hypereosinophilic syndrome (HES), while only weakly on those from normal donors. Because HES eosinophils contain abundant cytosolic phospholipase A2 (cPLA2) and 5-lipoxygenase (5-LO), we examined the roles of several enzymes involved in the metabolism of arachidonic acid in the PAF- or IL-5-induced CD69 expression on eosinophils. The CD69 expression induced by PAF and IL-5 on HES eosinophils and that by IL-5 on normal eosinophils were both inhibited by AA861 and MK-886, inhibitors of 5-LO activity. In addition, AACOCF3, a selective cPLA2 inhibitor, inhibited IL-5-induced CD69 expression on normal eosinophils, although it hardly affected either IL-5- or PAF-induced CD69 expression on HES eosinophils. Moreover, PAF alone induced CD69 only weakly on normal eosinophils, but exogenous arachidonic acid remarkably enhanced PAF-induced CD69 expression on them. These findings suggest that IL-5 activates both cPLA2 and 5-LO but PAF activates only 5-LO. It is suggested that 5-LO plays a critical role in the induction of CD69 on eosinophils.
- 1 January 2001
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 69 (1) , 105-112
Pivotal role of 5-lipoxygenase in the activation of human eosinophils: platelet-activating factor and interleukin-5 induce CD69 on eosinophils through the 5-lipoxygenase pathway
CD69 is an activation-related cell surface molecule on human eosinophils. It has been reported that interleukin (IL)-5, but not platelet-activating factor (PAF), can induce CD69 on human eosinophils in vitro. In this study, PAF induced CD69 intensely on eosinophils from patients with hypereosinophilic syndrome (HES), while only weakly on those from normal donors. Because HES eosinophils contain abundant cytosolic phospholipase A2 (cPLA2) and 5-lipoxygenase (5-LO), we examined the roles of several enzymes involved in the metabolism of arachidonic acid in the PAF- or IL-5-induced CD69 expression on eosinophils. The CD69 expression induced by PAF and IL-5 on HES eosinophils and that by IL-5 on normal eosinophils were both inhibited by AA861 and MK-886, inhibitors of 5-LO activity. In addition, AACOCF3, a selective cPLA2 inhibitor, inhibited IL-5-induced CD69 expression on normal eosinophils, although it hardly affected either IL-5- or PAF-induced CD69 expression on HES eosinophils. Moreover, PAF alone induced CD69 only weakly on normal eosinophils, but exogenous arachidonic acid remarkably enhanced PAF-induced CD69 expression on them. These findings suggest that IL-5 activates both cPLA2 and 5-LO but PAF activates only 5-LO. It is suggested that 5-LO plays a critical role in the induction of CD69 on eosinophils.
- Open Access
- 15 September 2000
- Published by American Society of Hematology in Blood
- Vol. 96 (6) , 2157-2162
Contribution of ecto-5′-nucleotidase to the inhibition of platelet aggregation by human endothelial cells
We studied the role of adenosine (Ado), which is generated from adenine nucleotides via the activity of ecto-5′-nucleotidase (ecto-5′-NT), in the inhibition of platelet aggregation by endothelial cells (ECs). The enzymatic activity of nucleotidases on human umbilical vein endothelial cells (HUVECs) was examined with regard to (1) the inhibition of adenosine diphosphate (ADP)–induced platelet aggregation and (2) the liberation of inorganic phosphate from adenine nucleotides. Adenosine 5′-monophosphate (AMP) preincubated with HUVECs significantly inhibited ADP-induced platelet aggregation. This was completely blocked by the treatment of HUVECs with a specific inhibitor of ecto-5′-NT, 5′-[αβ-methylene] diphosphate (APCP), or by the addition of an A2a receptor antagonist. Neither nitric oxide nor prostacyclin was involved in this inhibitory activity, suggesting that Ado generated in the incubation medium by the activity of 5′-NT on HUVECs inhibited platelet aggregation. When ADP was incubated on HUVECs, it lost most of its agonistic activity for platelets. Pretreatment of HUVECs with APCP at a concentration that abolished ecto-5′-NT activity partially restored ADP-induced platelet aggregation. Ecto-5′-NT contributes to EC function by inhibiting platelet aggregation in cooperation with ATP diphosphohydrolase, which degrades ADP to AMP.
- 15 September 2000
- Published by American Society of Hematology in Blood
- Vol. 96 (6) , 2157-2162
Open AccessContribution of ecto-5′-nucleotidase to the inhibition of platelet aggregation by human endothelial cells
We studied the role of adenosine (Ado), which is generated from adenine nucleotides via the activity of ecto-5′-nucleotidase (ecto-5′-NT), in the inhibition of platelet aggregation by endothelial cells (ECs). The enzymatic activity of nucleotidases on human umbilical vein endothelial cells (HUVECs) was examined with regard to (1) the inhibition of adenosine diphosphate (ADP)–induced platelet aggregation and (2) the liberation of inorganic phosphate from adenine nucleotides. Adenosine 5′-monophosphate (AMP) preincubated with HUVECs significantly inhibited ADP-induced platelet aggregation. This was completely blocked by the treatment of HUVECs with a specific inhibitor of ecto-5′-NT, 5′-[αβ-methylene] diphosphate (APCP), or by the addition of an A2a receptor antagonist. Neither nitric oxide nor prostacyclin was involved in this inhibitory activity, suggesting that Ado generated in the incubation medium by the activity of 5′-NT on HUVECs inhibited platelet aggregation. When ADP was incubated on HUVECs, it lost most of its agonistic activity for platelets. Pretreatment of HUVECs with APCP at a concentration that abolished ecto-5′-NT activity partially restored ADP-induced platelet aggregation. Ecto-5′-NT contributes to EC function by inhibiting platelet aggregation in cooperation with ATP diphosphohydrolase, which degrades ADP to AMP.
- Open Access
- 15 September 2000
- Published by American Society of Hematology in Blood
- Vol. 96 (6) , 2157-2162
Contribution of ecto-5′-nucleotidase to the inhibition of platelet aggregation by human endothelial cells
We studied the role of adenosine (Ado), which is generated from adenine nucleotides via the activity of ecto-5′-nucleotidase (ecto-5′-NT), in the inhibition of platelet aggregation by endothelial cells (ECs). The enzymatic activity of nucleotidases on human umbilical vein endothelial cells (HUVECs) was examined with regard to (1) the inhibition of adenosine diphosphate (ADP)–induced platelet aggregation and (2) the liberation of inorganic phosphate from adenine nucleotides. Adenosine 5′-monophosphate (AMP) preincubated with HUVECs significantly inhibited ADP-induced platelet aggregation. This was completely blocked by the treatment of HUVECs with a specific inhibitor of ecto-5′-NT, 5′-[αβ-methylene] diphosphate (APCP), or by the addition of an A2a receptor antagonist. Neither nitric oxide nor prostacyclin was involved in this inhibitory activity, suggesting that Ado generated in the incubation medium by the activity of 5′-NT on HUVECs inhibited platelet aggregation. When ADP was incubated on HUVECs, it lost most of its agonistic activity for platelets. Pretreatment of HUVECs with APCP at a concentration that abolished ecto-5′-NT activity partially restored ADP-induced platelet aggregation. Ecto-5′-NT contributes to EC function by inhibiting platelet aggregation in cooperation with ATP diphosphohydrolase, which degrades ADP to AMP.
- 15 September 2000
- Published by American Society of Hematology in Blood
- Vol. 96 (6) , 2157-2162
Open AccessContribution of ecto-5′-nucleotidase to the inhibition of platelet aggregation by human endothelial cells
We studied the role of adenosine (Ado), which is generated from adenine nucleotides via the activity of ecto-5′-nucleotidase (ecto-5′-NT), in the inhibition of platelet aggregation by endothelial cells (ECs). The enzymatic activity of nucleotidases on human umbilical vein endothelial cells (HUVECs) was examined with regard to (1) the inhibition of adenosine diphosphate (ADP)–induced platelet aggregation and (2) the liberation of inorganic phosphate from adenine nucleotides. Adenosine 5′-monophosphate (AMP) preincubated with HUVECs significantly inhibited ADP-induced platelet aggregation. This was completely blocked by the treatment of HUVECs with a specific inhibitor of ecto-5′-NT, 5′-[αβ-methylene] diphosphate (APCP), or by the addition of an A2a receptor antagonist. Neither nitric oxide nor prostacyclin was involved in this inhibitory activity, suggesting that Ado generated in the incubation medium by the activity of 5′-NT on HUVECs inhibited platelet aggregation. When ADP was incubated on HUVECs, it lost most of its agonistic activity for platelets. Pretreatment of HUVECs with APCP at a concentration that abolished ecto-5′-NT activity partially restored ADP-induced platelet aggregation. Ecto-5′-NT contributes to EC function by inhibiting platelet aggregation in cooperation with ATP diphosphohydrolase, which degrades ADP to AMP.
- Open Access
- 1 June 2000
- Published by Wiley in British Journal of Haematology
- Vol. 109 (4) , 875-881
Inhibition of complement‐mediated haemolysis in paroxysmal nocturnal haemoglobinuria by heparin or low‐molecular weight heparin
Complement (C′)‐mediated haemolysis in paroxysmal nocturnal haemoglobinuria (PNH) is mainly due to the deficiency of glycosyl phosphatidylinositol‐anchored membrane proteins with C′‐regulatory activities CD55 and CD59 in PNH‐affected red blood cells (RBCs). Hydrophobic insertion of C5b‐7 to RBC membranes, initiating the formation of a membrane attack complex, readily results in lysis of PNH RBCs due to the deficiency of CD59. We studied the significance of the electrostatic interactions between C5b‐6 and RBC membranes preceding the insertion of C5b‐7. In vitro, C′‐mediated lysis of PNH RBCs (assessed by sucrose haemolytic assay) was inhibited by heparin, low‐molecular weight heparin (LMWH) or protamine, indicating the significance of the electrostatic interactions between C′ components and RBC membranes in the process of C′‐mediated haemolysis. Neuraminidase‐treated PNH RBCs became resistant to C′ activation, suggesting that the sialic acid moieties on RBC membranes are involved in the interactions of RBC with C′ components. By using biotin‐labelled C7, we demonstrated that LMWH as well as heparin inhibited the insertion of C5b‐7 to RBCs, although they did not inhibit the incorporation of C7 into membrane‐associated C5b‐6. Neither heparin nor LMWH could inhibit the procoagulant alteration of PNH RBC membranes induced by C′ activation even at concentrations which inhibited the haemolysis completely. Because LMWH inhibited the C′‐mediated lysis of PNH RBCs in vitro at the range which induced a limited prolongation of activated partial thromboplastin time of normal plasma, we consider that LMWH may be useful for both the inhibition of haemolysis and the prevention of thrombosis, which often follow a haemolytic attack in PNH.
- 1 June 2000
- Published by Wiley in British Journal of Haematology
- Vol. 109 (4) , 875-881
Open AccessInhibition of complement‐mediated haemolysis in paroxysmal nocturnal haemoglobinuria by heparin or low‐molecular weight heparin
Complement (C′)‐mediated haemolysis in paroxysmal nocturnal haemoglobinuria (PNH) is mainly due to the deficiency of glycosyl phosphatidylinositol‐anchored membrane proteins with C′‐regulatory activities CD55 and CD59 in PNH‐affected red blood cells (RBCs). Hydrophobic insertion of C5b‐7 to RBC membranes, initiating the formation of a membrane attack complex, readily results in lysis of PNH RBCs due to the deficiency of CD59. We studied the significance of the electrostatic interactions between C5b‐6 and RBC membranes preceding the insertion of C5b‐7. In vitro, C′‐mediated lysis of PNH RBCs (assessed by sucrose haemolytic assay) was inhibited by heparin, low‐molecular weight heparin (LMWH) or protamine, indicating the significance of the electrostatic interactions between C′ components and RBC membranes in the process of C′‐mediated haemolysis. Neuraminidase‐treated PNH RBCs became resistant to C′ activation, suggesting that the sialic acid moieties on RBC membranes are involved in the interactions of RBC with C′ components. By using biotin‐labelled C7, we demonstrated that LMWH as well as heparin inhibited the insertion of C5b‐7 to RBCs, although they did not inhibit the incorporation of C7 into membrane‐associated C5b‐6. Neither heparin nor LMWH could inhibit the procoagulant alteration of PNH RBC membranes induced by C′ activation even at concentrations which inhibited the haemolysis completely. Because LMWH inhibited the C′‐mediated lysis of PNH RBCs in vitro at the range which induced a limited prolongation of activated partial thromboplastin time of normal plasma, we consider that LMWH may be useful for both the inhibition of haemolysis and the prevention of thrombosis, which often follow a haemolytic attack in PNH.
- 1 April 2000
- Published by Springer Nature in Inflammation Research
- Vol. 49 (4) , 177-183
Induction of the activation-related antigen CD69 on human eosinophils by type IIA phospholipase A 2
Objective: High levels of human type IIA phospholipase A2 (PLA2-IIA) have been found in the eosinophil-mediated inflammation sites, although the pathophysiological role of PLA2-IIA in the eosinophil activation has remained poorly understood. We investigated the effects of PLA2-IIA on eosinophil activation.¶Methods: Eosinophils were incubated with recombinant human PLA2-IIA or other stimuli, and then eosinophil peroxidase (EPO) (by colorimetric assay) and leukotriene C4 (by enzyme immunoassay) released in the incubation buffer were measured. Expression of CD11b and CD69 on the cell surface was also measured by flow cytometry (by mean fluorescence intensity (MFI)). EPO, LTC4, and CD11b are thought to be markers for early phase activation (occurred in an hour after stimulation), and CD69 is to be a marker for late phase activation (occurred after several hours).¶Results: While PLA2-IIA (5 μg/ml) did not induce any early phase activation, it induced significant expression of an activation-related antigen, CD69, on human blood eosinophils. The PLA2-IIA, when enzymatically inactivated by either p-bromophenacyl bromide or EDTA, lost its effect on the CD69 induction. Similarly to PLA2-IIA, several lysophospholipids (1 μg/ml) also induced CD69 on eosinophils significantly (control, 0.71 ± 0.11; PLA2-IIA, 3.29 ± 0.37*; lysophosphatidic acid, 2.57 ± 0.43*; specific MFI ± S.E.M., n = 4, *indicate p < 0.05 vs. control).¶Conclusions: PLA2-IIA induces CD69 expression on the eosinophils through its catalytic activity at least partly via the enzymatic products such as several lysophospholipids from the eosinophil membrane phospholipids. PLA2-IIA may contribute to the eosinophilic inflammation synergistically with other factors.
- 1 April 2000
- Published by Springer Nature in Inflammation Research
- Vol. 49 (4) , 177-183
Induction of the activation-related antigen CD69 on human eosinophils by type IIA phospholipase A 2
Objective: High levels of human type IIA phospholipase A2 (PLA2-IIA) have been found in the eosinophil-mediated inflammation sites, although the pathophysiological role of PLA2-IIA in the eosinophil activation has remained poorly understood. We investigated the effects of PLA2-IIA on eosinophil activation.¶Methods: Eosinophils were incubated with recombinant human PLA2-IIA or other stimuli, and then eosinophil peroxidase (EPO) (by colorimetric assay) and leukotriene C4 (by enzyme immunoassay) released in the incubation buffer were measured. Expression of CD11b and CD69 on the cell surface was also measured by flow cytometry (by mean fluorescence intensity (MFI)). EPO, LTC4, and CD11b are thought to be markers for early phase activation (occurred in an hour after stimulation), and CD69 is to be a marker for late phase activation (occurred after several hours).¶Results: While PLA2-IIA (5 μg/ml) did not induce any early phase activation, it induced significant expression of an activation-related antigen, CD69, on human blood eosinophils. The PLA2-IIA, when enzymatically inactivated by either p-bromophenacyl bromide or EDTA, lost its effect on the CD69 induction. Similarly to PLA2-IIA, several lysophospholipids (1 μg/ml) also induced CD69 on eosinophils significantly (control, 0.71 ± 0.11; PLA2-IIA, 3.29 ± 0.37*; lysophosphatidic acid, 2.57 ± 0.43*; specific MFI ± S.E.M., n = 4, *indicate p < 0.05 vs. control).¶Conclusions: PLA2-IIA induces CD69 expression on the eosinophils through its catalytic activity at least partly via the enzymatic products such as several lysophospholipids from the eosinophil membrane phospholipids. PLA2-IIA may contribute to the eosinophilic inflammation synergistically with other factors.